Liquid biopsy & ctDNA diagnostics
Detecting and quantifying circulating tumour DNA (ctDNA) in blood for companion oncology diagnostics and minimal-residual-disease (MRD) monitoring, replacing or supplementing tissue biopsy.
How it works
This is a procurement category, not a named manufacturer's product. As a paid service, Bioecon finds suppliers for your task, agrees configuration and specification, and arranges supply; the price is on request. Bioecon may receive a fee from suppliers — this is disclosed and does not affect the portal's grades or lists.
Technology
Liquid biopsy & ctDNA diagnostics — Evidence, registration route, funding and suppliers are on the technology page.
Blood-based detection and quantification of circulating tumor DNA (ctDNA) for cancer companion diagnostics and molecular residual disease (MRD) monitoring, replacing or supplementing tissue biopsy — led by Guardant Health, Natera and Foundation Medicine in the US, Sysmex Inostics in the EU, …
Links
- Import and registration route
- CHEM — Minpromtorg (registration) / Rospotrebnadzor (notification of …
- Capabilities
- Testing & analytics
Related items
Other categories for this technology
Analytical & testing services · Laboratory & analytical instruments
In the same node
Base editing · Bioelectronics experiment kits · Bioluminescence & marine fluorescent proteins · Breath-based diagnostics (breathomics) · Companion diagnostics platforms · CRISPR diagnostics · CRISPR educational kits · CRISPR screening as a service · All →